CADL Stock — Candel Therapeutics, Inc.

Candel Therapeutics, Inc. (CADL)

Updated October 16, 2026.

CADL is a Stock. Total return is 17.0% over the past 5.2 years, 69.5 points behind SPY at 86.5%.

Candel Therapeutics is a clinical-stage biopharmaceutical company developing immunotherapies for cancer, including CAN-2409 in Phase 2a trials for prostate cancer and non-small cell lung cancer, and CAN-3110 in Phase Ib trials for recurrent high-grade glioma, along with its proprietary enLIGHTEN Discovery Platform for identifying new viral immunotherapy candidates. The company does not currently have an established distribution schedule. This security appeals primarily to investors seeking exposure to early-stage cancer immunotherapy development rather than current income.

CADL performance versus SPY

Price and return data through 2026-10-16.

Total return is 17.0% over the past 5.2 years, 69.5 points behind SPY at 86.5%. Over the past year its total return — price change plus distributions reinvested — is 51.1%. Its deepest 1-year drawdown was 40.4%.

CADL key facts

Asset type

Stock

Asset class

Equity

Inception date

07/27/2021

Distribution frequency

None

Last close

$8.19 (as of 2026-10-16)

Market cap

$626,687,047

Average volume

1512786.0

Beta

-0.312

Payout ratio

0.0%

Forward P/E

43.4783

EPS

$-1.47

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

CADL risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 40.4%.

Who may consider CADL — and who may not

It is a weaker fit for investors who need monthly cash flow (CADL does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on CADL

• All tickers starting with C

Tagged: Healthcare.

Frequently asked questions